Lasma AB 200mg/10mg Tablet is a combination medication containing Acebrophylline 200mg and Montelukast 10mg, indicated for the management of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Acebrophylline acts as a bronchodilator and mucolytic agent, facilitating airway relaxation and reducing mucus viscosity, thereby improving airflow and easing breathing. Montelukast, a leukotriene receptor antagonist, helps in preventing bronchoconstriction and inflammation by inhibiting leukotriene-mediated effects, thus reducing asthma symptoms and frequency of exacerbations. This synergistic formulation offers both symptomatic relief and prophylactic benefits, enhancing pulmonary function and patient quality of life. Lasma AB is typically prescribed as a once-daily oral tablet, with dosage tailored to individual patient needs and clinical response. It is generally well tolerated; however, potential side effects may include headache, gastrointestinal disturbances, and hypersensitivity reactions. Caution is advised in patients with hepatic impairment or known hypersensitivity to any component. Regular monitoring and adherence to prescribed therapy are essential for optimal therapeutic outcomes. Lasma AB 200mg/10mg Tablet should be used under medical supervision, with consideration of patient-specific factors and concurrent medications to avoid adverse interactions.